BIODEXA PHARMACEUTICALS PLC
SPONSORED ADS · CUSIP 59564R880
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $2.67.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2025 | 4 |
| Q4 2025 | 8 |
| Q1 2026 | 7 |
| Q2 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2025 | 5 | 2 |
| Q1 2026 | 3 | 5 |
| Q2 2026 | 0 | 7 |
Biggest buyers
| None |
Biggest sellers
| SABBY MANAGEMENT, LLC | Sold out | -257.5k |
| ARMISTICE CAPITAL, LLC | Sold out | -97.5k |
| GAMMA Investing LLC | Sold out | -13.8k |
| UBS Group AG | Sold out | -127 |
| Hilton Head Capital Partners, LLC | Sold out | -30 |
| RHUMBLINE ADVISERS | Reduced | -16 |
| Caitong International Asset Management Co., Ltd | Sold out | -1 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| ARMISTICE CAPITAL, LLC 13G · institution new · filed 2026-02-17 | 10.0% |
| SABBY MANAGEMENT, LLC 13G · passive investor new · filed 2026-01-20 | 9.9% |
Fell to 5% or below in the last year: C/M CAPITAL PARTNERS, LP (0.0%, 2025-11-14)
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| RHUMBLINE ADVISERS 0.00% of their portfolio | 3 $8 | Reduced -16 |